Regeneron Pharmaceuticals, Inc. (REGN)

Schlusskurs vom Vortag:

$890.66

Offen:

$889.41

24-Stunden-Volumen:

91,763

Marktkapitalisierung:

$98.14B

Einnahmen:

$13.12B

Nettoeinkommen (Verlust:

$3.95B

KGV:

25.65

EPS:

35.06

Netto-Cashflow:

$3.67B

1W Leistung:

-0.86%

1M Leistung:

-7.28%

6M Leistung:

+13.58%

1J Leistung:

+11.41%

1-Tages-Spanne:

$888.52

$898.95

52-Wochen-Spanne:

$684.80

$998.33

Regeneron Pharmaceuticals, Inc. Stock (REGN) Company Profile

Firmenname

Regeneron Pharmaceuticals, Inc.

Sektor

Healthcare (1201)

Branche

Biotechnology (682)

Telefon

914-847-7000

Adresse

777 Old Saw Mill River Road, Tarrytown, NY

Mitarbeiter

6,763

Twitter

@regeneron

Nächster Verdiensttermin

2024-05-02

Neueste SEC-Einreichungen

REGN's Discussions on Twitter

Regeneron Pharmaceuticals, Inc. Stock (REGN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-01-12	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2023-11-09	Eingeleitet	Deutsche Bank	Hold
2023-11-03	Hochstufung	Raymond James	Mkt Perform → Outperform
2023-08-21	Hochstufung	Canaccord Genuity	Hold → Buy
2023-08-21	Bestätigt	Oppenheimer	Perform
2023-06-28	Herabstufung	Canaccord Genuity	Buy → Hold
2023-03-27	Hochstufung	SVB Securities	Market Perform → Outperform
2023-03-24	Hochstufung	Jefferies	Hold → Buy
2023-03-23	Hochstufung	Raymond James	Underperform → Mkt Perform
2023-01-30	Hochstufung	Cowen	Market Perform → Outperform
2023-01-20	Hochstufung	JP Morgan	Neutral → Overweight
2022-10-26	Herabstufung	Raymond James	Mkt Perform → Underperform
2022-10-17	Herabstufung	Evercore ISI	Outperform → In-line
2022-09-09	Hochstufung	Jefferies	Underperform → Hold
2022-09-09	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2022-07-25	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2022-07-13	Eingeleitet	Cantor Fitzgerald	Neutral
2022-06-06	Eingeleitet	Jefferies	Underperform
2022-05-23	Eingeleitet	SVB Leerink	Outperform
2022-01-05	Herabstufung	BofA Securities	Neutral → Underperform
2022-01-03	Hochstufung	Bernstein	Mkt Perform → Outperform
2021-12-15	Herabstufung	Bernstein	Outperform → Mkt Perform
2021-12-09	Fortgesetzt	Wells Fargo	Overweight
2021-12-07	Fortgesetzt	Cowen	Market Perform
2021-12-06	Eingeleitet	Goldman	Buy
2021-11-19	Fortgesetzt	BMO Capital Markets	Outperform
2021-11-05	Herabstufung	The Benchmark Company	Buy → Hold
2021-06-29	Eingeleitet	H.C. Wainwright	Buy
2021-01-25	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-01-13	Hochstufung	The Benchmark Company	Hold → Buy
2021-01-08	Hochstufung	Citigroup	Neutral → Buy
2020-10-05	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2020-08-20	Herabstufung	The Benchmark Company	Buy → Hold
2020-07-09	Hochstufung	SunTrust	Hold → Buy
2020-05-26	Hochstufung	Wells Fargo	Equal Weight → Overweight
2020-04-28	Herabstufung	Citigroup	Buy → Neutral
2020-04-17	Hochstufung	The Benchmark Company	Hold → Buy
2020-04-08	Eingeleitet	The Benchmark Company	Hold
2020-03-31	Eingeleitet	Wolfe Research	Peer Perform
2020-02-27	Eingeleitet	Barclays	Overweight
2020-02-26	Hochstufung	Canaccord Genuity	Hold → Buy
2020-02-26	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-02-25	Hochstufung	Jefferies	Hold → Buy
2020-02-11	Hochstufung	Argus	Hold → Buy
2019-12-24	Eingeleitet	Raymond James	Mkt Perform
2019-12-16	Herabstufung	Evercore ISI	Outperform → In-line
2019-12-13	Hochstufung	Credit Suisse	Neutral → Outperform
2019-11-12	Eingeleitet	SunTrust	Hold
2019-11-07	Hochstufung	Citigroup	Neutral → Buy
2019-10-17	Fortgesetzt	BofA/Merrill	Neutral
2019-09-23	Hochstufung	Guggenheim	Neutral → Buy

Alle ansehen

Regeneron Pharmaceuticals, Inc. Aktie (REGN) Neueste Nachrichten

Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?

Zacks Investment Research

Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?

Zacks Investment Research

Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a Turnaround

Zacks Investment Research

Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS

Zacks Investment Research

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases

GlobeNewswire Inc.

EXEL vs. REGN: Which Stock Is the Better Value Option?

Zacks Investment Research

Finanzdaten der Regeneron Pharmaceuticals, Inc.-Aktie (REGN)

Regeneron Pharmaceuticals, Inc. (REGN) Umsatz 2024

Regeneron Pharmaceuticals, Inc. (REGN) Nettogewinn 2024

Regeneron Pharmaceuticals, Inc. (REGN) Free Cashflow 2024

Regeneron Pharmaceuticals, Inc. (REGN) Gewinn je Aktie 2024

Regeneron Pharmaceuticals, Inc.-Aktie (REGN) Insiderhandel